KRYS
NEUTRAL
$259.0
Live
Krystal Biotech, Inc. · NASDAQ
Target $314.0
(+21.2%)
$122.8
52W Range
$298.3
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 13, 2026
Market cap
$7.62B
P/E
37.87
ROE
18.9%
Profit margin
52.6%
Debt/Equity
0.01
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
KRYS presents a dichotomy between exceptional operational efficiency and poor valuation metrics. The company exhibits a weak Piotroski F-Score (3/9), suggesting deteriorating financial trends despite a pristine balance sheet with nearly zero debt and a high current ratio (9.95). While gross margins are elite at 94.08%, the stock trades at a significant premium to its Graham Number ($80.18) and Intrinsic Value ($166.9). Heavy insider selling and a bearish technical trend offset the 'Strong Buy' analyst consensus, suggesting the current price reflects peak optimism.
Key Strengths
Exceptional gross margins of 94.08% indicating strong pricing power
Virtually debt-free balance sheet with a Debt/Equity ratio of 0.01
Extreme liquidity with a Current Ratio of 9.95
Successful transition from historical losses to consistent profitability
Strong analyst backing with a mean target price of $314.00
Key Risks
Significant overvaluation relative to intrinsic value ($259 vs $166.9)
Aggressive insider liquidation totaling $63.13M in the last 6 months
Low Piotroski F-Score (3/9) indicating weak fundamental momentum
Very high Price-to-Sales ratio (19.59) compared to typical healthcare benchmarks
Strongly bearish technical trend (10/100)
AI Fair Value Estimate
Based on comprehensive analysis
$178.5
-31.1% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
41
Moderate
25
75
65
40
0
AI Verdict
Overvalued Growth
Key drivers: Elite margins, Pristine balance sheet, Extreme valuation premium, Insider selling
Confidence
90%
Value
25/100
Ref P/E 37.87, P/S 19.59, Graham $80.18
Positives
- Forward P/E is lower than current P/E
Watchpoints
- Price far exceeds Graham Number ($80.18)
- P/S ratio of 19.59 is excessive
- Price is ~55% above Graham Number
Future
75/100
Ref Growth rates and Analyst Targets
Positives
- Strong revenue growth (17.5%)
- High analyst target price ($314)
- High operating margins (41.33%)
Watchpoints
- Recent Q/Q EPS growth decline (-36.1%)
Past
65/100
Ref Historical earnings progression
Positives
- Successful pivot to profitability in 2024
- Strong 5Y price appreciation (+264.6%)
Watchpoints
- History of significant earnings misses prior to 2024
Health
40/100
Ref Piotroski F-Score and Debt/Equity
Positives
- Debt/Equity 0.01
- Current Ratio 9.95
Watchpoints
- Piotroski F-Score of 3/9 (Weak)
Dividend
0/100
Ref Yield 0%
Positives
No standout positives identified.
Watchpoints
- No dividend paid
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$259.0
Analyst Target
$314.0
Upside/Downside
+21.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for KRYS and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
KRYS
Krystal Biotech, Inc.
Primary
|
+264.6% | +209.6% | +61.2% | +42.7% | +1.6% | -0.8% |
|
BRKR
Bruker Corporation
Peer
|
-14.9% | -28.5% | -13.1% | +20.3% | +4.6% | +4.0% |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
Peer
|
-23.4% | +107.3% | +265.3% | +85.2% | -10.6% | -8.0% |
|
IBRX
ImmunityBio, Inc.
Peer
|
-54.8% | +372.7% | +195.9% | +208.5% | -12.0% | -0.3% |
|
BIO
Bio-Rad Laboratories, Inc.
Peer
|
-49.6% | -35.1% | -15.9% | +12.3% | -1.7% | -5.4% |
KRY
Krystal Biotech, Inc.
Primary
5Y
+264.6%
3Y
+209.6%
1Y
+61.2%
6M
+42.7%
1M
+1.6%
1W
-0.8%
BRK
Bruker Corporation
Peer
5Y
-14.9%
3Y
-28.5%
1Y
-13.1%
6M
+20.3%
1M
+4.6%
1W
+4.0%
ARW
Arrowhead Pharmaceuticals, Inc.
Peer
5Y
-23.4%
3Y
+107.3%
1Y
+265.3%
6M
+85.2%
1M
-10.6%
1W
-8.0%
IBR
ImmunityBio, Inc.
Peer
5Y
-54.8%
3Y
+372.7%
1Y
+195.9%
6M
+208.5%
1M
-12.0%
1W
-0.3%
BIO
Bio-Rad Laboratories, Inc.
Peer
5Y
-49.6%
3Y
-35.1%
1Y
-15.9%
6M
+12.3%
1M
-1.7%
1W
-5.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
37.87
Forward P/E
24.48
PEG Ratio
N/A
P/B Ratio
6.2
P/S Ratio
19.59
EV/Revenue
17.35
EV/EBITDA
41.45
Market Cap
$7.62B
Profitability
Profit margins and return metrics
Profit Margin
52.64%
Operating Margin
41.33%
Gross Margin
94.08%
ROE
18.91%
ROA
8.44%
Growth
Revenue and earnings growth rates
Revenue Growth
+17.5%
Earnings Growth
+11.6%
Q/Q Revenue Growth
+17.52%
Q/Q Earnings Growth
+13.0%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.01
Low debt
Current Ratio
9.95
Strong
Quick Ratio
9.28
Excellent
Cash/Share
$28.32
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.1B
Gross Margin
93.8%
Op. Margin
41.3%
Net Margin
48.0%
Total Assets
$1.3B
Liabilities
$0.1B
Equity
$1.2B
Debt/Equity
0.09x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.1B
FCF Yield
97%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-04
$N/A
2026-02-17
$1.7
+5.8% surprise
2025-11-03
$2.66
+144.9% surprise
2025-08-04
$1.29
-10.2% surprise
Healthcare Sector Comparison
Comparing KRYS against 291 companies in the Healthcare sector
(20 bullish, 99 neutral, 172 bearish)
P/E Ratio
37.87
This Stock
vs
87.11
Sector Avg
-56.5%
(Discount)
Return on Equity (ROE)
18.91%
This Stock
vs
-49.88%
Sector Avg
-137.9%
(Below Avg)
Profit Margin
52.64%
This Stock
vs
-9.43%
Sector Avg
-658.0%
(Weaker)
Debt to Equity
0.01
This Stock
vs
3.74
Sector Avg
-99.8%
(Less Debt)
Revenue Growth
17.5%
This Stock
vs
80.78%
Sector Avg
-78.3%
(Slower)
Current Ratio
9.95
This Stock
vs
3.72
Sector Avg
+167.6%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
KRYS
Krystal Biotech, Inc.
|
NEUTRAL | $7.62B | 37.87 | 18.9% | 52.6% | $259.0 | |
|
BRKR
Bruker Corporation
|
BEARISH | $7.65B | - | -1.1% | -0.6% | $50.33 | Compare |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
BULLISH | $7.71B | 34.41 | 75.5% | 18.5% | $55.05 | Compare |
|
IBRX
ImmunityBio, Inc.
|
NEUTRAL | $7.52B | - | -% | -% | $7.28 | Compare |
|
BIO
Bio-Rad Laboratories, Inc.
|
NEUTRAL | $8.0B | - | -9.5% | -26.4% | $296.57 | Compare |
KRYS
Krystal Biotech, Inc.
NEUTRAL
Mkt Cap
$7.6B
P/E
37.9
ROE
18.9%
Price
$259.0
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-04 | KRISHNAN SUMA M | Officer, Director and Beneficial Owner | Sale | 25,000 | $6,580,270 |
| 2026-03-04 | KRISHNAN KRISH S | Chief Executive Officer | Sale | 25,000 | $6,579,164 |
| 2026-03-02 | ROMANO KATHRYN | Officer | Sale | 750 | $200,700 |
| 2026-02-27 | KRISHNAN SUMA M | Officer, Director and Beneficial Owner | Stock Award | 67,225 | - |
| 2026-02-27 | KRISHNAN KRISH S | Chief Executive Officer | Stock Award | 67,225 | - |
| 2026-02-27 | ROMANO KATHRYN | Officer | Stock Award | 8,050 | - |
| 2026-02-27 | JANNEY DANIEL SPENCER | Director | Sale | 11,803 | $3,252,824 |
| 2026-02-26 | JANNEY DANIEL SPENCER | Director | Sale | 60,161 | $16,149,383 |
| 2026-02-24 | JANNEY DANIEL SPENCER | Director | Option Exercise | 37,895 | $93,222 |
| 2026-02-19 | ROSSI DINO A | Director | Sale | 18,950 | $4,953,694 |
| 2026-02-19 | ROSSI DINO A | Director | Option Exercise | 18,950 | $166,570 |
| 2026-02-09 | ROMANO KATHRYN | Officer | Gift | 750 | - |
| 2026-02-09 | ROMANO KATHRYN | Officer | Sale | 12,500 | $3,401,705 |
| 2026-02-09 | ROMANO KATHRYN | Officer | Option Exercise | 12,500 | $794,375 |
| 2025-12-05 | KRISHNAN SUMA M | Officer, Director and Beneficial Owner | Gift | 5,000 | - |
KRISHNAN SUMA M
Officer, Director and Beneficial Owner
2026-03-04
25,000 shares
·
$6,580,270
KRISHNAN KRISH S
Chief Executive Officer
2026-03-04
25,000 shares
·
$6,579,164
ROMANO KATHRYN
Officer
2026-03-02
750 shares
·
$200,700
KRISHNAN SUMA M
Officer, Director and Beneficial Owner
2026-02-27
67,225 shares
KRISHNAN KRISH S
Chief Executive Officer
2026-02-27
67,225 shares
ROMANO KATHRYN
Officer
2026-02-27
8,050 shares
JANNEY DANIEL SPENCER
Director
2026-02-27
11,803 shares
·
$3,252,824
JANNEY DANIEL SPENCER
Director
2026-02-26
60,161 shares
·
$16,149,383
JANNEY DANIEL SPENCER
Director
2026-02-24
37,895 shares
·
$93,222
ROSSI DINO A
Director
2026-02-19
18,950 shares
·
$4,953,694
ROSSI DINO A
Director
2026-02-19
18,950 shares
·
$166,570
ROMANO KATHRYN
Officer
2026-02-09
750 shares
ROMANO KATHRYN
Officer
2026-02-09
12,500 shares
·
$3,401,705
ROMANO KATHRYN
Officer
2026-02-09
12,500 shares
·
$794,375
KRISHNAN SUMA M
Officer, Director and Beneficial Owner
2025-12-05
5,000 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
9 analysts
Wolfe Research
2026-03-27
Peer Perform
Guggenheim
2026-02-25
Buy
Buy
Citigroup
2026-02-18
Buy
Buy
Chardan Capital
2026-02-18
Buy
Buy
Jefferies
2026-02-17
Buy
Buy
Goldman Sachs
2026-02-02
Buy
Buy
B of A Securities
2026-01-22
Buy
Buy
Citigroup
2026-01-12
Buy
Buy
TD Cowen
2026-01-09
Buy
Buy
Citigroup
2026-01-09
Buy
Buy
Past News Coverage
Recent headlines mentioning KRYS from our newsroom.
Newest → oldest
No matching news yet.